Description

SoliRis 300mg Injection (Eculizumab) – Uses, Dosage, Side Effects & Price in Pakistan

SoliRis 300mg Injection contains eculizumab, a prescription monoclonal antibody and complement inhibitor. It is used to treat certain rare disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD) in eligible patients.

Eculizumab works by blocking complement protein C5, helping reduce harmful complement-system activity. Because treatment can significantly increase the risk of serious meningococcal infection, SoliRis must be administered under specialist medical supervision with appropriate vaccination and safety precautions.

What Is SoliRis 300mg Injection?

SoliRis contains eculizumab 300mg/30mL (10mg/mL) and is supplied as a single-dose vial for intravenous infusion. It is a humanized monoclonal antibody that targets complement protein C5.

Eculizumab is not a conventional chemotherapy medicine. Instead, it modifies the activity of the immune system’s complement pathway and is used for specific complement-mediated diseases.

The reference product Soliris is packaged by Alexion Pharmaceuticals, Inc. according to the current DailyMed record.

SoliRis 300mg Uses

SoliRis may be prescribed for the following approved conditions:

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Eculizumab is indicated for patients with PNH to reduce hemolysis, which is the destruction of red blood cells caused by uncontrolled complement activity.

Atypical Hemolytic Uremic Syndrome (aHUS)

SoliRis is used in patients with aHUS to inhibit complement-mediated thrombotic microangiopathy. This can help reduce abnormal complement activity responsible for damage to small blood vessels.

SoliRis is not indicated for Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS).

Generalized Myasthenia Gravis

SoliRis is indicated for generalized myasthenia gravis in adults and children aged 6 years and older who are anti-acetylcholine receptor (AChR) antibody positive.

Neuromyelitis Optica Spectrum Disorder

In adults who are anti-aquaporin-4 (AQP4) antibody positive, eculizumab is also indicated for the treatment of NMOSD.

How Does Eculizumab Work?

Eculizumab is a complement inhibitor. It binds to complement protein C5 and prevents its cleavage into C5a and C5b.

By blocking this part of the complement pathway, eculizumab reduces complement-mediated cell damage. In PNH, for example, this helps protect red blood cells from complement-mediated destruction.

SoliRis 300mg Dosage

The dose of eculizumab depends on the condition being treated, the patient’s age, and the treatment schedule.

For adults with PNH, the current FDA-approved regimen is:

• 600mg once weekly for the first 4 weeks
• 900mg during week 5
• 900mg every 2 weeks thereafter

For adults with aHUS, generalized myasthenia gravis, or NMOSD, the recommended regimen is:

• 900mg once weekly for the first 4 weeks
• 1,200mg during week 5
• 1,200mg every 2 weeks thereafter

SoliRis is supplied as a 300mg/30mL vial, so the 300mg strength refers to the amount contained in one vial and does not necessarily represent the patient’s complete treatment dose.

The exact dosage and treatment schedule must be determined by the specialist treating the patient.

How to Take SoliRis 300mg Injection

SoliRis is administered only by intravenous infusion.

• It must be diluted before administration.
• It should not be given as an IV push or bolus.
• Adult infusions are administered over approximately 35 minutes.
• Pediatric infusions may require 1 to 4 hours.
• Patients are monitored after the infusion for possible infusion-related reactions.

SoliRis should only be administered by trained healthcare professionals.

SoliRis 300mg Side Effects

Possible side effects vary according to the condition being treated.

Common adverse reactions reported in clinical studies include:

• Headache
• Nausea
• Back pain
• Nasopharyngitis
• Diarrhea
• Abdominal pain
• Upper respiratory infections
• Hypertension
• Vomiting
• Anemia
• Cough
• Peripheral edema
• Fever
• Musculoskeletal pain

Not every patient experiences these effects.

Serious Side Effects and Warnings

Serious Meningococcal Infection

The most important safety concern with eculizumab is the significantly increased risk of serious, life-threatening, or fatal meningococcal infections.

Patients should generally complete or update meningococcal vaccination against serogroups A, C, W, Y, and B at least 2 weeks before starting treatment, unless urgent treatment is medically necessary. If treatment must begin urgently in a patient who is not adequately vaccinated, antibacterial prophylaxis may be required according to the treating physician’s instructions.

Vaccination does not completely eliminate the risk of meningococcal infection.

Seek immediate medical attention for symptoms such as fever, severe headache, stiff neck, rash, confusion, or other signs of serious infection.

Other Infections

Because eculizumab affects the complement system, patients may have increased susceptibility to certain infections, including infections caused by encapsulated bacteria. Appropriate vaccinations and medical monitoring are important.

Infusion-Related Reactions

Infusion-related reactions can occur during administration. Healthcare professionals should monitor patients during and after infusion and manage reactions appropriately.

SoliRis 300mg Precautions

Before treatment, tell your doctor if you:

• Have an active infection.
• Have not received recommended meningococcal vaccinations.
• Have allergies or previous reactions to biological medicines.
• Are pregnant or planning pregnancy.
• Are breastfeeding.
• Are taking other prescription or non-prescription medicines.

Patients receiving eculizumab should follow the vaccination and infection-monitoring plan provided by their specialist.

SoliRis 300mg Drug Interactions

Eculizumab does not have the same type of conventional drug-metabolism interactions seen with many oral medicines. However, the treatment can affect immune function and infection risk.

Tell your doctor about all medicines, vaccines, supplements, and other treatments you receive. Your healthcare team should particularly review your vaccination status before treatment.

Pregnancy and Breastfeeding

If you are pregnant, planning pregnancy, or breastfeeding, discuss eculizumab treatment with your doctor.

The potential benefits and risks of treatment should be assessed individually, particularly because the diseases treated with eculizumab can themselves be serious.

Do not stop treatment because of pregnancy without speaking with your specialist.

SoliRis 300mg injection Storage

SoliRis should be stored according to the manufacturer’s instructions and handled by the healthcare facility administering the medicine.

The product is supplied as a refrigerated injectable biological medicine, and appropriate cold-chain handling is important. Keep the vial protected according to the original product labeling and do not use a damaged or improperly stored vial.

SoliRis 300mg injection Manufacturer

The current U.S. DailyMed record identifies Alexion Pharmaceuticals, Inc. as the packager of Soliris (eculizumab).

For a specific SoliRis 300mg product, always check the original packaging for the manufacturer, batch number, expiry date, and country of origin before publishing market-specific details.

SoliRis 300mg Price in Pakistan

The price of SoliRis 300mg Injection in Pakistan may vary depending on availability, importer, supplier, packaging, and market conditions.

For the latest SoliRis 300mg price in Pakistan, customers should check the current product listing or contact the pharmacy for updated pricing and availability.

Buy SoliRis 300mg Injection in Pakistan

SoliRis 300mg is a specialist prescription medicine and should only be obtained through a legitimate pharmaceutical supply channel and used under specialist medical supervision.

Because eculizumab requires specific vaccination and infection precautions, patients should not attempt to self-administer or arrange treatment without appropriate medical supervision.

Why Choose Impo Medic?

At Impo Medic, we aim to provide clear information and access to imported medicines while maintaining a responsible approach to specialist prescription products.

• Clear product information
• Imported medicine availability
• Updated pricing where available
• Online ordering support
• Assistance with product availability
• Responsible guidance for prescription medicines

FAQs About SoliRis 300mg injection (Eculizumab)

1. What is SoliRis 300mg used for?

SoliRis contains eculizumab and is used for certain patients with PNH, aHUS, generalized myasthenia gravis, and AQP4-antibody-positive NMOSD.

2. What is the active ingredient in SoliRis?

The active ingredient is eculizumab 300mg/30mL.

3. Is SoliRis a chemotherapy medicine?

No. Eculizumab is a complement inhibitor and monoclonal antibody, not conventional chemotherapy.

4. How is SoliRis 300mg injection administered?

SoliRis is administered as a diluted intravenous infusion by a healthcare professional. It must not be given as an IV push or bolus.

5. Why are meningococcal vaccines important with SoliRis?

Eculizumab substantially increases the risk of serious meningococcal infection. Recommended meningococcal vaccination should generally be completed or updated before treatment begins.

6. Can SoliRis cause infections?

Yes. Because eculizumab blocks part of the complement system, it increases susceptibility to certain serious infections, particularly meningococcal infection.

7. Does one SoliRis 300mg vial equal one treatment dose?

Not necessarily. One vial contains 300mg of eculizumab, while the prescribed dose depends on the disease and treatment schedule.

8. Can SoliRis be self-injected?

No. SoliRis is intended for intravenous infusion by qualified healthcare professionals.

Legal & Medical Disclaimer

This information is provided for educational purposes only and does not replace professional medical advice. SoliRis 300mg Injection (Eculizumab) is a specialist prescription medicine and should only be used under the supervision of a qualified healthcare professional. Do not start, stop, or change treatment without medical advice.